ABSTRACT Effect of WEB 1881 FU (nebracetam) on hypoxia and ischemia-induced impairment of 2-deoxyglucose (2DG) uptake and CAI field potentials induced by hypoxia and hypoxia/hypoglycemia (ischemia) in rat brain slices was evaluated and compared to the findings obtained with pentobarbital and idebenone. Hippocampal and cortical slices were exposed to 15 20 min of ischemia, and then these slices were returned to oxygenated and glucose-containing buffer for 6 hr. Ischemia reduced both 30 mM KCI-induced 2DG uptake and CAI field potentials elicited by the stimulation of Schaffer collaterals in the hippocampus. Pretreatment of nebracetam at 1 mM or pentobarbital at 0.1 mM attenuated a decline of 2DG uptake and CAI field potentials under the condition of ischemia. In addition, nebracetam and pentobarbital relatively recovered the increase of 2DG uptake in the hippocampus under hypoxia for 45 min. Furthermore, these drugs also attenuated the decline of 2DG uptake induced by 10 mM glutamate for 20 min. However, treatment with idebenone did not recover the deficit of 2DG uptake and CAI field potential. The present result suggests that neb racetam and pentobarbital exert neuroprotective actions against not only ischemia but also glutamate toxicity.
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Many model systems for the study of cere bral ischemia and/or hypoxia have been de veloped. Rat brain slices were developed as a model for investigating the effects of ischemia on glucose metabolism, as this metabolism is an early functional indicator of cell damage (1) . Recently we demonstrated that the glu cose uptake under a condition of mild to se vere hypoxia/hypoglycemia was reduced in hippocampal slices, especially in the CAI and dentate regions, and this reduction of 2DG uptake was prevented by pretreatment with N methyl-D-aspartate receptor antagonists and low Ca2+-high Mg2+ solution (2) . Further more, we observed that this treatment pre vented the reduction of the amplitude of field potentials in the hippocampal CAI elicited by the stimulation of Schaffer collaterals under the ischemic condition in vitro. Thus we have suggested the usefulness of a deficit of glucose uptake in brain slices as a model of ischemia to evaluate the neuroprotective effect of drugs.
WEB 1881 FU (nebracetam, 4-aminomethyl 1-benzyl-pyrrolidin-2-one-hemifumarate) reduced hypoxic lethality in mice and decreased the ex tent of ATP and phosphocreatine depletion in rabbit brain following cerebral ischemia (3) .
In an in vitro study, nebracetam protected against impairment of the release of DA from striatal slices under the condition of ischemia (4) . These findings suggest that nebracetam exerts a neuroprotective action against ische mia.
The pyramidal cells of the CA1 region of the rat hippocampus are peculiarly vulnerable to ischemia in vivo (5) . In the present experi ment, therefore, we investigated the effect of nebracetam on the deficit of 2DG uptake and field potentials in the hippocampal slices in duced by ischemia in vitro. This result was compared to those obtained with other drugs: pentobarbital and idebenone.
MATERIALS AND METHODS

Materials
Male Wistar rats (7-10 weeks old) were used. The animals were decapitated and the cerebrum was removed quickly from the skull. Parasagital cerebral and hippocampal slices (450-,um thick) were prepared using a tissue chopper.
The composition of the control Krebs solu tion, equilibrated with 95% 02:5% C02, was: 129 mM NaCI, 1.3 mM MgSO4, 22.4 mM NaHCO3, 1.2 mM KH2PO4, 4.2 mM KCI, 10.0 mM glucose and 1.5 mM CaC12. The buffer was maintained at a pH of 7.3 7.4. The glu cose concentration of hypoglycemia was set at 0 mM, with the sucrose concentration kept at 10 mM. Hypoxia solution was pre-equilibrated with 95% N2: 5% CO2 for at least 1 hr. Tissue slice preparations were preincubated with standard Krebs solution for 1 hr.
2-Deoxyglucose uptake
Slices were exposed to 20 min of hypoxia and hypoglycemia (ischemia) or maintained in normal buffer for an additional 20 min. Fol lowing this procedure, the slices were returned to oxygenated and glucose-containing buffer for 6 hr. Then the slices were incubated with normal solution containing 0.2 pCi/ml of 
Electrophysiology
Field potentials were usually recorded through glass micropipettes filled with 3 M NaCl (DC resistance, 0.5 -1 M Ohm). The hippocampal CAI field potentials evoked by Schaffer collateral stimulation were recorded. Stimulation pulses of 0.05 msec in duration and 0.1 0.9 mA in intensity were applied, and the intensity which produced a supra maximal response was selected. Extracellular recordings of population responses in the stra tum pyramidale of the CAI region were made. The amplitude of the population spike was measured from the crest of the EPSP to the most negative portion of the spike.
Drugs
The drugs used in this study were: WEB 1881 FU (nebracetam, 4-aminomethyl-l-benzyl pyrrolidin-2-one-hemifumarate; Nippon Boehring er Ingelheim), idebenone (6-(10-hydroxydecyl) 2,3-dimethoxy-5-methyl-1,4-benzoquinone, Ta keda Chemical Industries) and pentobarbital (Tanabe). In some experiments, rotatory isomers of WEB 1881 FU: (-)-isomer (WEB 1881 FU-X), (+)-isomer (WEB 1881 FU-Y) and racemate (WEB 1881 FU, nebracetam) were used. Nebracetam, its isomers and pentobarbital were dissolved in distilled water, and idebenone was dissolved in ethanol at a 
RESULTS
2-Deoxyglucose uptake and ischemia
The 30-mM KCl-induced 2DG uptake after 20-min ischemia significantly decreased in hip pocampal slices after a 6-hr washout (Fig. 1) . The 2DG uptake of the control hippocampal slices was 33.8 ± 2.0 dpm/,ug protein/45 min (n = 3). The 2DG uptake of control slices was designated as 100%. The 30-mM KCl-induced 2DG uptake in ischemic hippocampal slices declined to 17.4 ± 1.6 dpm/,ug protein/45 min (n = 6) after a 6-hr washout. This result is well-consistent with our previous report (2) . Hippocampal slices were exposed to the drug containing Krebs Ringer for 20 min prior to the ischemia and throughout the ischemia (20 min). Slices were then returned to normal buff er for 6 hr. The treatment of nebracetam at 1 mM and pentobarbital at 100,uM significantly attenuated the decline of the 2DG uptake in duced by ischemia (Fig. 2) .
In contrast, idebenone at 0.01-10 ,u M did not prevent the deficit of 2DG uptake against ischemia; and at 100 /uM, idebenone caused an exacerbation of the ischemic deficit of 2DG uptake.
2-Deoxyglucose uptake and hypoxia
The 2DG uptake was observed under the hypoxic condition for 45 min. Under hypoxia, 2DG uptake in the hippocampal slices in creased to 279 ± 14% (n = 12) that of normo xic slices. The hypoxia-induced 2DG uptake increase was significantly attenuated by neb racetam in a dose-dependent manner and also by pentobarbital at 10,uM (Fig. 3) . In the normoxic condition, nebracetam at 10 and 100 ,uM did not change the 2DG uptake.
2-Deoxyglucose uptake and glutamate
The 30-mM KCl-induced 2DG uptake after the application of glutamate at 10 mM for 20 min decreased remarkably in the cerebral cor tex and moderately in the hippocampus in comparison with the control slices (Fig. 1) .
Because glutamate at 10 mM significantly de creased 2DG uptake in the cerebral cortex after a 6-hr washout (Fig. 1) , neuroprotective effect of nebracetam was examined using cor tical slices (Fig. 4) .
Cortical slices were exposed to the drug containing Krebs Ringer for 20 min prior to the application of glutamate at 10 mM and throughout the application of glutamate. Slices were then returned to normal buffer for 6 hr. The treatment of nebracetam at 0.1 and 1 mM and pentobarbital at 100 ,u M attenuated the decline of 2DG uptake induced by glutamate (Fig. 4) . On the other hand, idenbenone at 0.1-10 ,u M did not prevent it. 
Electrophysiology
The amplitude of CAI field potentials de creased markedly depending upon the dura tion (10-20 min) of the ischemic condition (data were not shown). The CAI field poten tials of slices exposed to 15-min ischemia were decreased by about 70% over a 6-hr washout. Therefore, hippocampal slices were exposed to the drug containing Krebs Ringer for 20 min prior to the ischemia and throughout the ischemia (15 min). Slices were then returned to normal buffer for 6 hr.
The application of nebracetam and pento barbital attenuated the decline of amplitude of field potentials in ischemic slices in a dose related manner (Figs. 5 and 6 ). On the other hand, idebenone at 0.1-10 MM did not pro tect against the decline of field potentials (Figs. 5 and 6 ).
To determine whether the action of neb racetam appears in a stereo-selective manner, we examined the effect of the racemate (neb racetam), and the ( ) and (+ )-isomers on the decline of field potentials induced by ischemia. The (+)-isomer (WEB 1881 FU-Y) but not the (-)-isomer (WEB 1881 FU-X) efectively showed a protective action (Fig. 7) .
DISCUSSION
In the present study, ischemia for 20 min caused a decline of 2DG uptake and 15-min ischemia decreased the CAI field potentials in hippocampal slices after a 6-hr washout. This is well-consistent with our previous result (2) . Pretreatment of nebracetam at 1-1000 u M attenuated the ischemia-induced deficit of 2DG uptake and field potentials in hippocam pal slices.
Furthermore, nebracetam at 10 and 100 u M also attenuated the marked increase of 2DG uptake under the hypoxic condition, but the same concentration of this drug did not change the 2DG uptake under the normal condition. Cerebral ischemia causes a marked reduction of brain ATP and phosphocreatine levels in rats (6) . A recent biochemical study has shown that pretreatment of nebracetam for 7 days diminishes the reduction of ATP and phosphocreatine concentration in rabbit brain following cerebral ischemia (3). In addi tion, nebracetam protected against impairment of striatal function under the conditions of hypoglycemia, NaCN and oligomycin, which inhibited mitochondrial ATP synthesis (4). Nebracetam did not change the dopamine re lease under normal conditions (4). These evi 6 . Effect of nebracetam, pentobarbital and idebenone on the decline of CAI field potentials induced by ischemia for 15 min. CAI field potentials were evoked by the stimulation of Schaffer collaterals (0.05 msec, 0.9 mA). All records were conducted after a 6-hr washout. The amplitude of CAI field potential in normal slices (C) was designated as 100%. Values in the figure are means ± S.E. from 6 to 12 animals. ##P < 0 .01 vs. normal control; *P < 0.05, **P < 0.01 vs. ischemia (Duncan's multiple-range test). (9) . Thus the mechanisms of N-methyl-D-aspartate receptor mediated brain injury have been the most ex tensively studied (9 11). The mechanism of protection by nebracetam is unknown, and the precise mechanism should be clarified in the future. However, the protective effect of nebracetam on the decline of 2DG uptake induced by ischemia and gluta mate may be due to a decrease in the lethal increase of intracellular Ca 2+ by activating the Ca 2+ pump and/or inhibiting Ca 2+ entry. This possibility was suggested previously (4) . We demonstrated that neuroprotection of neb racetam was produced stereo-specifically by the enantiomers of nebracetam. Thus the (+ ) isomer was more effective than the (-)-isom er in neuroprotective action. This is consistent with dopamine release data showing that the (+ )-isomer was more effective than the (-) isomer in their protective action against im pairment of dopamine release under the ische mic condition (our unpublished observation). However, we cannot rule out the possibilities of other actions of nebracetam.
A biochemical experiment suggested that nebracetam acts as an agonist on M1-musca rinic receptors (12) . A long-term administration of nebracetam produced the down-regulation of M1-muscarinic receptors in the hippocam pus and striatum (12) . Actually, the deficits of 2DG uptake and CA1 field potential induced by ischemia were strongly reversed by a long term pretreatment of M1 receptor agonists (our unpublished observation).
Therefore, the agonistic action of neb racetam on M1-muscarinic receptor may be in volved in the mechanism of neuroprotection against the deficit of 2DG uptake as well as CAI field potentials induced by ischemia and glutamate. Cholinesterase inhibitors, such as physostigmine, tetrahydroaminoacridine and amiridine, and nebracetam reserved a memory deficit in the 3-panel runway task in ischemic models (13) .
Pentobarbital prevented ischemia and glutamate-induced a deficit of 2DG uptake of hippocampal and cortical slices at 10 100 ,UM. In an in vivo experiment, it was reported that pentobarbital prevented the ischemia-in duced neuronal death of CA1 pyramidal cells (14, 15) . Thus pentobarbital may ameliorate neuronal damage to the hippocampal and cor tical cells by either delaying the failure in energy metabolism (16) or enhancing the GABAergic inhibitory effect (17) .
In contrast to nebracetam and pentobarbi tal, idebenone did not show any protective ac tion against a decline of 2DG uptake and CA1 field potential induced by ischemia and gluta mate in our ischemia model. Miyamoto et al. (18) examined the effect of idebenone on glutamate-induced cytotoxicity in N-18-RE-105 cells and demonstrated that idebenone (0.1 3 u M) produced marked pro tection against the cytotoxicity of glutamate. This disagreement may be due to the differ ence of experimental method.
In conclusion, nebracetam has a neuro protective action similar to that of pentobarbital using an in vitro ischemia model. Although the neuroprotective effect of idebenone against glutamate toxicity has been reported, in our experimental model, its neuroprotective effect could not be evaluated. This neuro protective effect of nebracetam may result in the amelioration of memory deficit in the ischemic model in vivo.
